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STUDY QUESTION: What is the relationship between maternal paracetamol intake during the masculinisation programming window
(MPW, 8–14 weeks of gestation) and male infant anogenital distance (AGD), a biomarker for androgen action during the MPW?
SUMMARY ANSWER: Intrauterine paracetamol exposure during 8–14 weeks of gestation is associated with shorter AGD from birth to
24 months of age.
WHAT IS ALREADY KNOWN: The increasing prevalence of male reproductive disorders may reﬂect environmental inﬂuences on foe-
tal testicular development during the MPW. Animal and human xenograft studies have demonstrated that paracetamol reduces foetal tes-
ticular testosterone production, consistent with reported epidemiological associations between prenatal paracetamol exposure and
cryptorchidism.
STUDY DESIGN, SIZE, DURATION: Prospective cohort study (Cambridge Baby Growth Study), with recruitment of pregnant women
at ~12 post-menstrual weeks of gestation from a single UK maternity unit between 2001 and 2009, and 24 months of infant follow-up. Of
2229 recruited women, 1640 continued with the infancy study after delivery, of whom 676 delivered male infants and completed a medicine
consumption questionnaire.
PARTICIPANTS/MATERIALS, SETTING, METHOD: Mothers self-reported medicine consumption during pregnancy by a question-
naire administered during the perinatal period. Infant AGD (measured from 2006 onwards), penile length and testicular descent were
assessed at 0, 3, 12, 18 and 24 months of age, and age-speciﬁc Z scores were calculated. Associations between paracetamol intake during
three gestational periods (<8 weeks, 8–14 weeks and >14 weeks) and these outcomes were tested by linear mixed models. Two hundred
and twenty-ﬁve (33%) of six hundred and eighty-one male infants were exposed to paracetamol during pregnancy, of whom sixty-eight were
reported to be exposed during 8–14 weeks. AGD measurements were available for 434 male infants.
MAIN RESULTS AND THE ROLE OF CHANCE: Paracetamol exposure during 8–14 weeks of gestation, but not any other period, was
associated with shorter AGD (by 0.27 SD, 95% CI 0.06–0.48, P = 0.014) from birth to 24 months of age. This reduction was independent of
body size. Paracetamol exposure was not related to penile length or testicular descent.
LIMITATIONS, REASONS FOR CAUTION: Confounding by other drugs or endocrine-disrupting chemicals cannot be discounted. The
cohort was not fully representative of pregnant women in the UK, particularly in terms of maternal ethnicity and smoking prevalence. There is
likely to have been misclassiﬁcation of paracetamol exposure due to recall error.
WIDER IMPLICATIONS OF THE FINDINGS: Our observational ﬁndings support experimental evidence that intrauterine paracetamol
exposure during the MPWmay adversely affect male reproductive development.
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Cancer Research Fund International, the Medical Research Council (UK), the Newlife Foundation for Disabled Children, the Evelyn Trust, the
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Introduction
Male genital disorders at birth (hypospadias and cryptorchidism) and
reproductive disorders in adulthood (poor semen quality and testicular
germ cell cancer) are common, and may be increasing in prevalence
(Bay et al., 2006). Skakkebaek et al. (2001) proposed that these disor-
ders could arise from foetal Leydig and Sertoli cell dysfunction, resulting
in androgen insufﬁciency and impaired germ cell development—the tes-
ticular dysgenesis syndrome (TDS). There has been much interest in
possible environmental causes of TDS, with recent attention turning to
mild analgesics, including paracetamol (acetaminophen) (Kristensen
et al., 2011). Paracetamol readily crosses the placenta (Rayburn et al.,
1986) and is used during pregnancy by 30–70% of women in the
Western world (Shaheen et al., 2002; Werler et al., 2005; Rebordosa
et al., 2008; Kristensen et al., 2011; Snijder et al., 2012; Lupattelli et al.,
2014; Vesterholm Lind et al., 2015). Leffers and colleagues were the ﬁrst
to demonstrate that gestational exposure of male rats to paracetamol
inhibits masculinisation, through a reduction in testicular testosterone
production (Kristensen et al., 2011, 2012). Subsequently, use of a xeno-
graft model demonstrated that administration of paracetamol at the
equivalent of a human therapeutic dose for 7 days reduces human fetal
testicular testosterone production (van den Driesche et al., 2015),
although another group had previously found no effect of 1–3 days of
paracetamol exposure on testosterone production by human foetal tes-
tes in vitro (Mazaud-Guittot et al., 2013).
Epidemiological studies of gestational paracetamol exposure and
TDS have focused on hypospadias and cryptorchidism, with no signiﬁ-
cant associations reported for the former (in adjusted models) and
conﬂicting results for the latter (Aselton et al., 1985; Correy et al.,
1991; Rebordosa et al., 2008; Feldkamp et al., 2010; Jensen et al.,
2010; Kristensen et al., 2011; Wagner-Mahler et al., 2011; Snijder
et al., 2012; Lind et al., 2013). Such studies require large cohorts to
obtain sufﬁcient numbers of these infrequent outcomes. Anogenital
distance (AGD) is an alternative biomarker of foetal testicular function,
which in animal models reﬂects androgen action during the masculin-
isation programming window (MPW), the developmental period dur-
ing which sufﬁcient androgen exposure must occur to ensure
subsequent normal differentiation and growth of male reproductive
organs (Welsh et al., 2008). In humans, the MPW is estimated to be
8–14 weeks of gestation (Welsh et al., 2008). A shorter AGD in males
has been associated with cryptorchidism, hypospadias, less masculine
play behaviour in childhood, and poor semen quality, infertility, small
testes and low serum testosterone levels in adulthood (Dean and
Sharpe, 2013; Thankamony et al., 2014; Pasterski et al., 2015).
Another measure that reﬂects androgen action during the MPW in
rodents is penile length (Welsh et al., 2008), although in humans it has
been associated only with hypospadias and cryptorchidism
(Thankamony et al., 2009, 2014), not adult male reproductive out-
comes (Eisenberg et al., 2011, 2012; Khan et al., 2012).
Our objective, therefore, was to investigate the relationship
between maternal paracetamol intake during pregnancy, particularly
during the postulated MPW, and male infant genital developmental
outcomes, with the hypothesis that paracetamol exposure during the
MPW, but not before or afterwards, reduce AGD, and may also
shorten penile length and impair testicular descent. We also hypothe-
sised that any paracetamol-related reduction in AGD in males would
not be seen in females, who generate signiﬁcantly lower levels of
androgens in utero (Robinson et al., 1977). To our knowledge, no pre-
vious studies have examined these speciﬁc associations.
Materials andMethods
Study design
Mothers and infants were recruited to the Cambridge Baby Growth Study
(CBGS), a large prospective cohort study (Prentice et al., 2015) (Fig. 1).
Mothers (n = 2229) were recruited from routine ultrasound clinics at ~12
post-menstrual weeks of gestation at the Rosie Maternity Unit,
Addenbrooke‘s Hospital, Cambridge, between April 2001 and March
2009. The unit supports a mixed urban and rural community. Mothers
were excluded from the study if they were aged <16 years or were unable
to give consent. Written informed consent was obtained from all mothers
by a research nurse.
One thousand six hundred and forty women continued with the infancy
study after delivery. For the analysis of male infant genital developmental
outcomes (AGD, penile length and testicular descent), mother–infant
dyads were included if the infant was male and the mother had completed
a questionnaire during the perinatal period, including questions on drug
exposure during pregnancy. This subset (676 mothers, 681 male offspring)
was representative of the whole cohort with regard to maternal age, pre-
pregnancy body mass index (BMI), deprivation index, ethnicity and parity,
but mothers were less likely to be smokers (22/673 (3.3%) versus 64/953
(6.6%), corrected χ2 = 8.41, P = 0.004).
Measurement of AGD was introduced to the study protocol in March
2006, so only 434/681 (63.7%) male infants had AGD measured. This
group was also representative of the entire CBGS cohort, apart from
maternal smoking prevalence (10/430 (2.3%) versus 76/1130 (6.3%), cor-
rected χ2 = 9.28, P = 0.002).
For the analysis of female infant AGD, mother–infant dyads were
included if the infant was female, the mother had completed a medicine
consumption questionnaire and AGD was measured. This subset (397
mothers, 401 female offspring) was similarly representative of the whole
CBGS cohort, apart from maternal smoking prevalence (9/397 (2.3%) ver-
sus 77/1244 (6.2%), corrected χ2 = 8.55, P = 0.003).
Maternal demographic characteristics and
paracetamol exposure
A printed questionnaire was given to women at the time of recruitment
with instructions that it should be completed in time for collection ‘after
your baby is born’ (the time period was not further speciﬁed, but mothers
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were asked to record the date they completed the questionnaire). The ques-
tionnaire gathered information on maternal demographic characteristics, and
also asked: ‘Have you taken any medicine during this pregnancy?’ Women who
answered ‘yes’ were further instructed to complete a table with the following
headings: ‘Name’, ‘Disease’, ‘Daily Dose’, ‘No. of days’ and ‘Gestational Week(s)’.
The top row of the table displayed ‘paracetamol’ as an example medication.
Women were considered to have been exposed to paracetamol if they
reported taking ‘paracetamol’, ‘co-codamol’, ‘co-dydramol’ or ‘acetamino-
phen’. Paracetamol intake was categorised by gestational period, where
speciﬁed (<8 weeks, 8–14 weeks or >14 weeks). We additionally collated
data on gestational exposure to ibuprofen, aspirin, codeine and dihydroco-
deine, but numbers of exposed male infants were too small for meaningful
analysis (all ≤10).
Examinations and anthropometric
measurements
Infants were examined and measured as newborns, as far as possible in the
ﬁrst 2 weeks of life, either in hospital or at home visits. They were then re-
examined during clinic visits at 3, 12, 18 and 24 months of age.
Birth weight as measured at delivery by midwives was taken from health
records. Subsequent examinations and measurements were carried out by
research nurses, as previously described (Thankamony et al., 2009). AGD,
and for males, penile length and testicular descent distance, were mea-
sured to the nearest 0.1 mm using Vernier callipers (DialMax, Wiha
Premium Tools, Schonach, Germany). AGD was measured from the
centre of the anus to the junction of smooth perineal skin and rugated skin
of the scrotum in males, and to the posterior convergence of the four-
chette in females. Penile length was measured from the inferior edge of the
pubic bone to the tip of the ﬂaccid penis (excluding the foreskin).
Testicular descent distance was measured from the superior edge of the
pubic bone to the superior aspect of the testis after manipulation into the
scrotum. Cryptorchidism was deﬁned as one or more testes not present
in the inferior half of the scrotum for at least a few moments after
manipulation.
Ethical approval
The study was approved by the local research ethics committee and
adhered to the Declaration of Helsinki for Medical Research involving
Human Subjects.
Statistical analyses
Differences in maternal and infant characteristics were assessed using the
t-test and Mann–Whitney U test for continuous variables, and chi-square
test for categorical variables.
In view of the high correlation between left- and right-sided testicular
descent distances at each time point (r = 0.89–0.93, P all < 0.0005), we
present ﬁndings for the average of both distances.
AGD, penile length, testicular descent distance, body weight and
gestation-corrected age at each time point (0, 3, 12, 18 and 24 months)
approximated normal distributions. To effectively utilise repeated
Figure 1 Flowchart for the study population. Abbreviations: CBGS, Cambridge Baby Growth Study; AGD, anogenital distance.
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outcome measurements at 0–24 months, we employed Z scores, which
represent the number of standard deviations (σ) an element (X) is from
the population mean (μ) (Z score = (X − μ)/σ). We ﬁrst generated Z
scores, adjusted for gestation-corrected age, for AGD (males and females
separately), penile length and testicular descent distance at each time
point. We also calculated Z scores for body weight using British 1990 ref-
erence data (Freeman et al., 1995). We then used linear mixed models to
test the relationships between paracetamol exposure and the repeated
outcome measures. Separate models were generated for each gestational
period (at any time in pregnancy, <8 weeks, 8–14 weeks and >14 weeks
of gestation) and each outcome (AGD, penile length and testicular descent
distance). Models using a ﬁrst-order autoregressive covariance matrix to
account for repeated and correlated measurements at different time
points within an individual produced the best ﬁt according to the Akaike
Information Criterion (Akaike, 1974). We further adjusted for body weight
Z score at each time point, and paracetamol exposure during other gesta-
tional periods, where relevant. We did not include other maternal covari-
ates (age, deprivation index, BMI, fasting blood glucose, parity, smoking,
method of delivery or ethnicity) in the models, as they were not signiﬁ-
cantly associated with AGD, penile length or testicular descent distance.
Differences in prevalence of cryptorchidism by paracetamol exposure
were assessed using chi-square test followed by logistic regression with
adjustment for body weight and gestation-corrected age.
We performed a sensitivity analysis in the majority of male infants with
AGD measurements who were born full-term (gestational age ≥37 weeks)
and not low birth weight (birth weight ≥2.5 kg) (n = 414).
All P-values were two-sided and P < 0.05 was considered statistically
signiﬁcant. Data were analysed using SPSS, version 21.0 (IBM Corporation,
New York, USA).
Results
Six hundred and eighty-one male offspring of six hundred and seventy-
six mothers were included in the analysis of male infant genital devel-
opmental outcomes (Fig. 1). The mean ± SD post-menstrual age at
completion of the questionnaire, where known (n = 611 mothers),
was 39.8 ± 10.8 weeks. A total of 313/611 (52.1%) questionnaires
were completed before birth and 519/611 (84.9%) before 3 months
postnatally.
Two hundred and twenty-ﬁve male infants (33.0%) were reported
as being exposed to paracetamol at least once during pregnancy. Of
the 224 mothers who took paracetamol, data on timings of exposure
were available for 186: 25 (13.4%) took paracetamol at <8 weeks of
gestation, 68 (36.6%) during 8–14 weeks and 117 (62.9%) at >14
weeks; 23 mothers (12.4%) took paracetamol during more than one
of the three periods. The median total dose consumed during preg-
nancy was 3.0 g (range 0.5–360.0 g). The most common indications
for taking paracetamol were headache or migraine (133/224, 59.4%)
and infection (41/224, 18.3%) (Supplementary Table I).
There were no differences in any demographic or birth variables
between mothers or male infants by exposure to paracetamol at any
time during pregnancy (Table I), or by exposure at <8 weeks, 8–14
weeks or >14 weeks of gestation (data not shown). Only one infant
had hypospadias.
Overall in CBGS, 465 of 1305 mothers (35.6%) consumed para-
cetamol during pregnancy, exposing 467 of 1315 male and female
infants (35.5%). The difference between the proportions of male and
female infants exposed to paracetamol in utero (225/681 (33.0%)
versus 242/634 (38.2%)) narrowly failed to achieve statistical
signiﬁcance (corrected χ2 = 3.55, P = 0.06). After excluding those for
whom timings of exposure were unavailable (n = 93 mothers), 125
of 1212 mothers (10.3%) reported taking paracetamol in the ﬁrst tri-
mester (12 weeks) of pregnancy.
Associations between paracetamol exposure
and AGD in males
Four hundred and thirty-four male infants had AGD measured at one
or more time points (mean 3.8 AGD measurements per infant), of
whom 141 (32.5%) were exposed to paracetamol at least once during
pregnancy (Fig. 1). Of these, 47 were reported to be exposed during
8–14 weeks of gestation, of whom 1 infant was also exposed at both
<8 weeks and >14 weeks and another 11 infants were exposed at
>14 weeks. In the unadjusted model, paracetamol exposure during 8–
14 weeks of gestation was associated with an AGD between birth and
24 months of age that was shorter by 0.28 SD (95% CI 0.06–0.49,
P = 0.012) (Supplementary Table II). This difference was not explained
by body weight or additional exposure to paracetamol at <8 or >14
weeks (adjusted model: P = 0.014) (Table II). Further addition of a body
weight Z score × exposure interaction term also did not attenuate the
association (data not shown). The reduction in AGD in male infants
exposed to paracetamol during 8–14 weeks appeared to be consistent
from birth to 24 months of age (Fig. 2, Supplementary Fig. 1,
Supplementary Table III), and there was no signiﬁcant interaction
between paracetamol exposure during 8–14 weeks and time point of
AGD measurement when we added this interaction term to the model
(P = 0.98). Exposure during any other gestational period was not asso-
ciated with AGD (Table II).
In a sensitivity analysis restricted to the 414 male infants with AGD
measurements who were born full-term and not low birth weight,
exposure to paracetamol during 8–14 weeks of gestation was also
associated with shorter AGD, by 0.28 SD (95% CI 0.07–0.49,
P = 0.011) in the model adjusted for body weight and exposure at <8
and >14 weeks.
Associations between paracetamol exposure
and other male genital outcomes
Data on penile length were available for 677 infants (mean 4.0 mea-
surements per infant) and data on testicular descent distance were
available for 662 infants (mean 3.6 measurements per infant). Neither
penile length nor testicular descent distance was signiﬁcantly asso-
ciated with paracetamol exposure during any gestational period
(Table II, Supplementary Table II, Supplementary Table IV). We also
found no signiﬁcant association between paracetamol exposure and
cryptorchidism at any postnatal time point (data not shown), although
our numbers were small (overall prevalence 33/650 (5.1%) at birth
and 62/424 (14.6%) at any age).
Associations between paracetamol exposure
and AGD in females
Data on AGD were available for 401 female infants (mean 3.8 mea-
surements per infant), of whom 148 (36.9%) were reported as being
exposed to paracetamol at least once during pregnancy (Fig. 1,
Supplementary Table V). Gestational paracetamol exposure (at any
time, <8 weeks, 8–14 weeks or >14 weeks) was not associated with
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AGD between birth and 24 months of age (data not shown). Female
infants exposed to paracetamol did, however, have a signiﬁcantly long-
er gestation than unexposed female infants (40.1 ± 1.2 weeks versus
39.7 ± 1.6 weeks, P = 0.004) (Supplementary Table V), with a smaller
proportion of exposed infants being born prematurely (i.e. at <37
weeks, 1/148 (0.7%) versus 12/253 (4.7%), corrected χ2 = 3.71,
P = 0.054).
Discussion
Summary of main ﬁndings
In this prospective study, we found a signiﬁcant negative association
between reported paracetamol exposure during the postulated MPW
(8–14 weeks of gestation) and AGD, a marker of intrauterine
androgen action (Welsh et al., 2008), in male infants. This association
was consistent postnatally across 0–24 months of age, and was inde-
pendent of body weight.
Interpretation of ﬁndings
Although the association between paracetamol exposure and AGD
was modest in size and not highly signiﬁcant, it may represent a true
effect of paracetamol on foetal androgen action, for several reasons.
Firstly, the association was robust to a more stringent sensitivity ana-
lysis (full-term males who were not low birth weight). Secondly, the
relationship was found only for paracetamol exposure during 8–14
weeks of gestation, and persisted after adjustment for exposure at <8
and >14 weeks—consistent with extrapolations from animal studies
that this period represents the programming window for normal
reproductive tract masculinisation (Welsh et al., 2008). Thirdly, our
.............................................................................................................................................................................................
Table I Characteristics of male infants included in the analysis of male infant genital developmental outcomes (n = 681)
and their mothers (n = 676). Values are mean ± SD or median (interquartile range) for continuous variables, n (%) for
categorical variables.
Characteristics Exposed to paracetamol at any
time during pregnancy
Not exposed to paracetamol
at any time during pregnancy
Pa
Mothers n= 224 n= 452
Age (years) 33.5 ± 3.9 33.5 ± 3.9 0.82
Pre-pregnancy BMI (kg/m2) 23.5 (21.5, 26.0) 22.8 (20.9, 26.0) 0.08
Ethnicityb
White 129 (95.6) 297 (96.1) 0.99
Other 6 (4.4) 12 (3.9)
Current smoker
No 216 (96.4) 437 (96.9) 0.93
Yes 8 (3.6) 14 (3.1)
Parity
0 95 (42.4) 201 (44.5) 0.81
1 92 (41.1) 184 (40.7)
≥2 37 (16.5) 67 (14.8)
Index of multiple deprivation (units) 7.7 (6.4, 10.5) 7.6 (6.4, 11.6) 0.98
Completion of questionnaire (post-menstrual weeks) 39.7 ± 10.8 40.2 ± 10.9 0.54
Male infants n= 225 n= 456
Gestation (weeks) 39.8 ± 1.3 39.8 ± 1.7 0.75
Birth weight (kg) 3.56 ± 0.48 3.58 ± 0.55 0.58
Birth AGD (cm)c 1.96 ± 0.61 1.96 ± 0.59 0.99
Birth penile length (cm) 3.14 ± 0.54 3.14 ± 0.49 0.99
Birth testicular descent distance (cm)
Right 5.07 ± 0.68 5.12 ± 0.67 0.45
Left 5.08 ± 0.73 5.13 ± 0.70 0.51
Congenital cryptorchidismd
No 210 (95.0) 407 (94.9) 0.99
Yes 11 (5.0) 22 (5.1)
Abbreviation: AGD, anogenital distance.
aP-values: comparing exposed and unexposed mothers/infants. Mann–Whitney U test for pre-pregnancy BMI and index of multiple deprivation; t-test for other continuous variables;
chi-square test for categorical variables (with Yates’ continuity correction for 2 × 2 tables).
bData on ethnicity are missing for 232 mothers.
cData on birth AGD are missing for 389 infants.
dData on congenital cryptorchidism are missing for 31 infants.
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ﬁndings are consistent with experimental models of paracetamol
exposure: administration to rats of paracetamol at 150 mg/kg/day
during the MPW resulted in a reduction in AGD of ~2 SD (Kristensen
et al., 2011); and a therapeutic regimen of paracetamol (20 mg/kg,
three times daily) for 7 days was sufﬁcient to decrease human foetal
testicular testosterone production by 45% in a xenograft model (van
den Driesche et al., 2015). Fourthly, a trend towards reduced AGD at
3 months of age in Danish male infants exposed to paracetamol during
the ﬁrst and second trimesters has recently been reported in abstract
form (Vesterholm Lind et al., 2015). Fifthly, three epidemiological stud-
ies have associated gestational paracetamol exposure with another
indicator of foetal androgen action, cryptorchidism (Jensen et al.,
2010; Kristensen et al., 2011; Snijder et al., 2012); indeed, one study
reported a strongest association with prolonged exposure during 8–14
weeks of gestation (Jensen et al., 2010). Sixthly, we found no effect of
paracetamol exposure on AGD in girls, consistent with its actions
being mediated via decreased testicular testosterone production
rather than a direct effect on the perineum or overall growth, and
making statistical confounding a less likely explanation for the associ-
ation seen in boys. Finally, we observed a concomitant but non-
signiﬁcant shortening of penile length with paracetamol exposure dur-
ing 8–14 weeks, providing further evidence of possible impaired
androgenisation.
Arguing against an anti-androgenic effect of paracetamol is a lack of
signiﬁcant association with testicular descent distance or cryptorchid-
ism in this study, compared with previous conﬂicting reports. One
possible explanation is that our study was underpowered to detect an
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Figure 2 Anogenital distance (AGD) at 0–24 months in relation to
paracetamol exposure during 8–14 weeks of gestation in male infants.
A break has been included in the y axis to more clearly demonstrate
the differences between the groups. Data represent the means and
error bars represent SEM. The total number of infants (n = 408) is
less than the number of male infants with AGD and paracetamol
exposure data in Cambridge Baby Growth Study (CBGS) (n = 434)
because it does not include infants who were exposed to paracetamol
during pregnancy but at an unknown time point.
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effect of paracetamol on testicular descent: the only previous epi-
demiological studies to demonstrate an association with cryptorchid-
ism recruited 2800–47 400 boys (Jensen et al., 2010; Kristensen et al.,
2011; Snijder et al., 2012), considerably more than our 681.
Furthermore, testicular descent is inﬂuenced by other hormones than
androgens (Hughes and Acerini, 2008), so not all cases of cryptorchid-
ism will be due to foetal androgen deprivation, and the strength of any
relationship with paracetamol exposure may therefore be weaker than
that of AGD (Dean and Sharpe, 2013).
The mechanism by which paracetamol may disrupt foetal androgen-
isation remains unclear. Paracetamol is a cyclooxygenase (COX)-2
inhibitor (Kristensen et al., 2012), and early work with other COX
inhibitors implicated the arachidonic acid cascade in the masculinisa-
tion of male mouse embryos (Gupta and Goldman, 1986). However,
parallel determinations of ex vivo testicular testosterone and prosta-
glandin production have indicated that the anti-androgenic effects of
paracetamol are independent of prostaglandins, and furthermore are
not related to insulin-like 3 (INSL3) production, Leydig cell numbers
or gonocyte apoptosis (Kristensen et al., 2012). Recent in vivo work
has demonstrated downregulation of the steroidogenic enzymes
Cyp11a1 and Cyp17a1 in the testes of rat fetuses exposed to high-
dose paracetamol (350 mg/kg/day) during the MPW (van den
Driesche et al., 2015), which is supported by steroidogenic proﬁling
data showing impaired conversion of progesterone to 17α-hydroxy-
progesterone by CYP17A1, and possibly other downstream enzymes,
in human adrenocortical carcinoma cells exposed to paracetamol
in vitro (Holm et al., 2015). The mechanisms by which paracetamol
might alter gene expression, however, are unknown.
An anti-androgenic effect of paracetamol during the MPW could
have important public health implications, for several reasons. Firstly,
paracetamol is used during the ﬁrst 20 weeks of gestation by 54% of
women in the UK (Shaheen et al., 2002), resulting in the exposure of
large numbers of male infants. Secondly, there is limited evidence from
epidemiological studies that deﬁciency in foetal androgens may be
associated with hypospadias and cryptorchidism at birth, and infertility,
poor semen quality, reduced serum testosterone levels and prostate
cancer in adulthood (Dean and Sharpe, 2013; Thankamony et al.,
2014). Thus, paracetamol exposure could potentially be contributing
to the apparent increase in prevalence of these disorders (Bay et al.,
2006). Finally, paracetamol would not be acting alone on foetal andro-
genisation: pregnant women are ubiquitously exposed to numerous
other anti-androgenic compounds, which may exert stronger effects
on male reproductive development in combination than individually
(Christiansen et al., 2012).
We incidentally found that gestational paracetamol exposure in
females, but not males, was associated with a signiﬁcantly longer ges-
tation (by an average of 2.8 days) and a trend towards a lower inci-
dence of preterm birth (0.7% versus 4.7%). Remarkably, a
retrospective Hungarian study reported an identical increase in mean
gestational age of infants exposed to paracetamol during pregnancy
(2.8 days), with a signiﬁcant reduction in preterm deliveries (3.5%
versus 9.2%), although they did not distinguish between male and
female offspring (Czeizel et al., 2005). The authors speculated that
paracetamol may prolong pregnancy via a reduction in prostacyclin
synthesis, consistent with ﬁndings from a randomised controlled trial
showing that low-dose aspirin (another COX inhibitor) also reduced
preterm delivery (CLASP (Collaborative Low-dose Aspirin Study in
Pregnancy) Collaborative Group, 1994). However, another observa-
tional study found no signiﬁcant association between paracetamol
prescriptions and preterm birth (Thulstrup et al., 1999), and a large
prospective study reported that women using paracetamol during
the third trimester had a signiﬁcantly increased risk of preterm deliv-
ery (although in subgroup analyses this persisted only for mothers
with pre-eclampsia, who may have been taking paracetamol for
hypertension-related headache) (Rebordosa et al., 2009). Given the
above, the fact that the association was not seen in males in our
study, the repeated statistical testing we have undertaken without
corrections, and the likely inﬂuence of length bias (infants born at
term had a higher probability of paracetamol exposure because of
the longer duration of the third trimester), we feel on balance that
our result likely reﬂects chance rather than a true effect of paraceta-
mol on gestational length.
We also incidentally found a non-signiﬁcant trend towards a higher
prevalence of intrauterine paracetamol exposure in female infants
(38%) than in male infants (33%). We can see no way in which such
exposure would alter the sex ratio, which is determined at conception,
but other explanations (such as differential indications for analgesic
consumption in mothers carrying male and female offspring) cannot be
excluded completely.
Limitations and strengths of the study
Our study has several limitations. Firstly, although we believe that con-
founding by indication for paracetamol consumption is unlikely, we
cannot discount confounding by other drugs or endocrine-disrupting
chemicals. Secondly, our sample size was relatively small (n = 434 for
male AGD measurements, with missing data points), which limited the
study‘s precision and statistical power. It also precluded analyses of
dose–response relationships for paracetamol and AGD, the effects of
other mild analgesics, or the association between paracetamol expos-
ure and hypospadias, and may have resulted in type-II errors in our
analyses of other male genital developmental outcomes. Thirdly, our
cohort was not fully representative of pregnant women in the UK, par-
ticularly in terms of maternal ethnicity and smoking prevalence, and
mothers who completed the questionnaire differed signiﬁcantly in
smoking prevalence from those who did not, raising the possibility of
selection bias and limiting the generalisability of our results. Finally,
there is likely to have been misclassiﬁcation of paracetamol exposure
due to recall error. We collected data on medication consumption
from a single questionnaire given to mothers at recruitment (~12
weeks of gestation) but completed an average of 6 months after the
MPW, by which time mothers may have been unable to accurately
recall their earlier paracetamol intake. Certainly, the proportion of
mothers (of all infants) in CBGS who admitted to gestational paraceta-
mol consumption (36%) was lower than has been reported in most
studies that administered questionnaires during, rather than after,
pregnancy (40–54%) (Shaheen et al., 2002; Rebordosa et al., 2008;
Kristensen et al., 2011; Vesterholm Lind et al., 2015), with a
Netherlands study being the one exception (30%) (Snijder et al.,
2012). Furthermore, MacLeod and colleagues reported that only 31%
of women correctly remembered ﬁrst-trimester exposure to over-
the-counter medications 15 months later (Feldman et al., 1989).
However, arguing against time-dependent underreporting is the fact
that the proportion of mothers in our study who recalled taking
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paracetamol in the ﬁrst 12 weeks of pregnancy (10%) was similar to
those from studies that administered questionnaires during the ﬁrst tri-
mester (9–30%) (Rebordosa et al., 2008; Snijder et al., 2012). In add-
ition, studies that administered questionnaires postnatally have tended
to describe higher, rather than lower, prevalences of gestational para-
cetamol consumption (49–70%), including during the ﬁrst trimester
(47–54%) (Werler et al., 2005; Feldkamp et al., 2010; Lupattelli et al.,
2014)—although this may in part be explained by the different popula-
tions being studied (generally higher prevalence in North America ver-
sus lower prevalence in Europe). In support of our study design, we
included paracetamol as an example medication in our questionnaire,
which may increase reporting of mild analgesia consumption by >85%
(Kristensen et al., 2011). Additionally, underreporting of paracetamol
consumption would be expected to bias results towards the null
hypothesis, which argues against the association with AGD being a
type-I error.
Our study’s strengths include the following: use of a well-
characterised birth cohort; ascertainment of gestational paracetamol
intake before AGD measurement in the majority of cases; use of AGD
as our primary measure of intrauterine androgen action, which is more
sensitive than hypospadias or cryptorchidism (Kristensen et al., 2011);
and measurement of AGD from the centre of anus to the posterior
edge of the scrotum (rather than to the anterior or posterior base of
the penis), which has been shown to be the most reliable and repeat-
able measurement of AGD (Dean and Sharpe, 2013).
Conclusion and implications
Our study provides novel and interesting data that support the
hypothesis that intrauterine paracetamol exposure during the MPW
may adversely affect male reproductive development. However, these
ﬁndings are preliminary, and will need to be conﬁrmed by larger,
carefully-designed prospective studies using paracetamol exposure
data collected concurrently throughout pregnancy.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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